Gilead Sciences, Inc. vs SoFi Technologies Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while SoFi Technologies Inc trades at $15.74 (market cap $20.23B). The key difference: Gilead Sciences, Inc. is far larger — about 9× SoFi Technologies Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and SoFi Technologies Inc for 60 Days on average.
| GILD | SOFI | |
|---|---|---|
Market Cap | $182.09B | $20.23B |
Volume | 4,960,247 | 32,692,405 |
Sector | Health | Financials |
52-Week High | $155.80 | $32.21 |
52-Week Low | $116.74 | $15.15 |
Typical Hold Time | 111 Days | 60 Days |
Enterprise Value | $205.15B | $20.37B |
Dividend Yield | 2.23% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
SOFI stock trades at $15.61, down 0.95% on the day, with a bearish technical signal and mixed sentiment. Revenue grew to $3.61B in 2025, with net income of $481.32M, but cash flow from operations remains negative. The company has beaten EPS estimates in recent quarters, with Q3 2026 results expected soon. Analyst consensus is a Buy with a $21.58 price target, though technical indicators suggest near-term pressure.
Outlook: SOFI offers growth potential with strong revenue expansion and a diversified fintech platform, but faces risks from negative operating cash flow, high valuation multiples, and sensitivity to interest rates. The stock's current discount to analyst targets may present opportunity, but investors should weigh execution risks and macroeconomic headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →